ProCE Banner Activity

Phase III ARAMIS Trial: Quality-of-Life Outcomes With Darolutamide + ADT vs Placebo + ADT in Patients With Nonmetastatic Castrate-Resistant Prostate Cancer

Slideset Download
Conference Coverage
Darolutamide improves outcomes while maintaining quality of life in nonmetastatic CRPC.

Released: June 02, 2019

Expiration: May 31, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro